登录新浪财经APP 搜索【信披】查看更多考评等级 1、江苏亚虹医药科技股份有限公司（以下简称"公司"）近日收到欧洲药品管理局（以下简称"EMA"） 的通知，公司产品APL-1702（CEVIRA）拟用于治疗宫颈高级别鳞状上皮内病变（HSIL）患者的上市 许可申请已获得EMA受理。 2、上市许可申请获得受理后，产品仍需通过后续审评审批环节，能否成功上市及具体上市时间存在不 确定性。即使在获批后，其最终能否实现商业目标亦存在一定的不确定性。上述产品上市许可申请获得 受理事项，对公司近期业绩不会产生重大影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将 严格按照有关规定对项目后续进展及时履行信息披露义务。 证券代码：688176 证券简称：亚虹医药 公告编号：2026-006 江苏亚虹医药科技股份有限公司 自愿披露关于APL-1702上市许可申请 成功获得欧洲药品管理局受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、产品情况 APL-1702是一款全球首创、中国首发的光动力治疗产品，由盐酸氨酮 ...

Core Viewpoint - APL-1702, a product developed by the company for treating High-Grade Squamous Intraepithelial Lesion (HSIL), has had its Phase III clinical trial results published in the prestigious journal "Med" by Cell Press, indicating a significant step in the product's development [1][2] Group 1: Product Information - APL-1702 is a photodynamic therapy product that combines drug and device components, designed as a non-surgical local treatment for HSIL [2] - The product consists of APL-1702 ointment and a device, currently under review by the National Medical Products Administration (NMPA) in China [2] Group 2: Clinical Trial and Publication - The results of the international, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial for APL-1702 have been published online in "Med," a top-tier journal in the medical field [1] - "Med" is recognized as a flagship journal of Cell Press, following "Cell" and "Chem," and is classified as a Q1 journal in the Journal Citation Reports (JCR) [1] Group 3: Market and Regulatory Considerations - The approval and market launch of APL-1702 remain uncertain as it is still undergoing the review process by the NMPA, with potential commercial success also being uncertain [2] - The publication of the clinical trial data is not expected to have a significant impact on the company's recent performance [2]